Highlights Newsletter 2 This newsletter presents you the following key sessions: Watch the video interview with Arnoud Méjean, MD, PhD, about the results of the phase III CARMENA trial: sunitinib alone is not inferior to cytoreductive nephrectomy + sunitinib in patients with metastatic renal cell carcinoma MONALEESA-3 demonstrates that ribociclib plus fulvestrant is an effective and safe first- and second-line treatment option for postmenopausal women with hormone-receptor positive, HER2-negative advanced breast cancer Maintenance low-dose chemotherapy prolongs survival of children with high-risk rhabdomyosarcoma Longer survival with first-line pembrolizumab compared to platinum-based chemotherapy in patients with NSCLC and a PD-L1 tumour proportion score of 1% or more Adjuvant mFOLFIRINOX associated with a significantly longer overall and progression free survival in patients with resected pancreatic ductal adenocarcinoma